Kornimate/medical-research-clean huggingface dataset:
causes and outcomes of community acquired pneumonia

Conditions: Community Acquired Pneumonia

Summary: this is a descriptive clinical research aiming: * to describe the clinical spectrum and clinical characteristics of community acquired pneumonia (cap) in patients admitted to hospital * to identify the etiology of cap and the antibiotic sensitivity of the isolated organisms * to identify the risk factors that influence the severity of cap

in vietnam, the range and relative contribution of organisms causing cap remain unclear, largely because diagnostic tools are limited and clinical research uncommon. an improved understanding of the risk factors, etiology and clinical outcomes of cap in vietnam would contribute to improved approaches to patient diagnosis and clinical management. this will be achieved by following the clinical and laboratory progress and treatment outcomes of in-patients diagnosed with cap from admission to discharge. comparative analyses will be between subgroups including survivor and non-survivor, severe cap and non-severe cap, known etiology and unknown etiology, sirs, sepsis, severe sepsis and shock septic.

Eligibility criteria:
inclusion criteria: * patients \> or = 18 years of age * patient meets the criteria of pneumonia (below), established within 36h of hospitalization * patient is not hospitalized or residing in a long-term-care facility within 14 days before the onset of symptoms * patient has not been at a referral hospital for \>2 days before admission to the study hospital * informed consent to participate in the study is provided exclusion criteria: * severe immunosuppression as judged by the enrolling physician (e.g. hiv, leukemia, lymphoma, chemotherapy for solid tumors, long-term corticosteroid use or other immunosuppressive drugs) * known active tuberculosis or current treatment for tuberculosis
phase 1 dose-escalating study of mm-398 (irinotecan sucrosofate liposome injection) plus intravenous cyclophosphamide in recurrent or refractory pediatric solid tumors

Conditions: Recurrent or Refractory Solid Tumors; Ewing Sarcoma; Rhabdomyosarcoma; Neuroblastoma; Osteosarcoma

Summary: this is a phase 1 study of the combination of two drugs: mm-398 and cyclophosphamide. the goal is to find the highest dose of mm-398 that can be given safely when it is used together with the chemotherapy drug cyclophosphamide.


Eligibility criteria:
inclusion criteria: * histologically or cytologically-confirmed ewing sarcoma, rhabdomyosarcoma, neuroblastoma, or osteosarcoma * disease progression after prior therapy in locally advanced or metastatic setting * measurable or evaluable disease based on the response evaluation criteria in solid tumors (recist v1.1) criteria * age 12 months to \<21 years * adequate bone marrow reserves, hepatic function, and renal function * recovered from effects of any prior surgery or cancer therapy * patients 18 years or older will provide written consent. a parent or legal guardian of a patient \<18 years of age will provide informed consent and patients 11 to 18 years of age will provide written assent or as per participating institutional policy. exclusion criteria: * clinically significant gastrointestinal disorders * nyha class iii or iv congestive heart failure, ventricular arrhythmias or uncontrolled blood pressure * active infection or unexplained fever * known hypersensitivity to any of the components of mm-398 or other liposomal products * recent investigational therapy * pregnant or breast feeding; females of child-bearing potential must test negative for pregnancy at the time of enrollment

Keywords: pediatric mm-398 cyclophosphamide irinotecan
effects of an immersive virtual reality intervention

Conditions: Nurse's Role; COVID-19 Pandemic; Mental Stress

Summary: some recent studies demonstrated caregivers may experience negative emotions such as anxiety and sadness, which may also affect normal treatment during the epidemic. as the pandemic continues, mental health support, encouragement , and a sense of purpose are needed to support healthcare workers.


Eligibility criteria:
inclusion criteria: * registered nurses (rn) who work in target departments were included. the target departments mainly included internal medicine, surgical, emergency department, where nurses had direct mutual engagement with patients. exclusion criteria: * nurses who have not been involved in the covid-19 volunteer service.
trial of safe water storage among people living with hiv

Conditions: Diarrhea; Waterborne Disease; HIV

Summary: environmental health-related pathogens include faecal-oral, diarrhoeagenic microbes that may be transmitted via drinking water and are related to sanitation and hygiene. previous research has suggested that safeguarding household drinking water against recontamination may be a critical intervention that can reduce risks of diarrheal diseases and may be especially important for people living with hiv/aids (plwha) and other vulnerable populations (clasen et al. 2007). the investigators propose here a randomised, controlled trial of a household safe storage container for drinking water in a well defined, hiv-impacted population in peri-urban lusaka, zambia. after a baseline data collection period (9 months) half of all households (150 households) will be given a safe water storage container specifically designed to prevent recontamination of water in household use. all households will be followed for an additional 9 months. results of this study will help determine whether this promising water quality intervention can reduce diarrhoea and related outcomes in this and similar vulnerable populations.

specific aim #1: to assess environmental health-related risk and outcomes in a low income peri-urban area of zambia with a high percentage of people living with hiv/aids (plwha) (longitudinal observational cohort study and baseline) (year 1). we will assemble a rich dataset on environmental health-related risk factors in a well defined population, with a focus on household drinking water quality and other water, sanitation, and hygiene (wsh) exposures. specific aim #2: to quantify the wsh-related disease burden among plwha, compared with those without hiv/aids (individual and household level stratification) (conclusion of baseline). after nine months of data collection, we will perform an initial analysis to determine wsh-related risk by hiv status. specific aim #3: to assess the impact of a water quality intervention on the longitudinal prevalence of highly credible gastrointestinal illness (hcgi) among plwha (randomized controlled trial, year 2). we will conduct a randomised, controlled trial of a safe water storage intervention. we will assess the health impacts of this intervention, with particular focus on the high-risk groups of plwha and children under 5 years of age.

Eligibility criteria:
inclusion criteria: * resident of misisi compound, lusaka * willing to participate in the study * is able to give informed consent and does so * household has one or more children who are aged 48 months or less at the start of the trial * the household stores drinking water in the home exclusion criteria: * not a resident of misisi compound, lusaka * unwilling to participate in the study * unable to give informed consent or chooses not to participate * household does not have one or more children aged 48 months or less at the start of the trial * the household does not store drinking water in the home

Keywords: environmental health diarrhea water hiv
biodistribution of [11c]acetoacetate/[18f]fluorodeoxyglucose in subjects with risk factors for alzheimer's disease

Conditions: Mild Cognitive Impairment

Summary: this is a single center imaging study that will recruit 60 participants who are enrolled in the effect of a ketogenic diet on alzheimer's disease biomarkers and symptoms: brain energy for amyloid transformation in ad (beat-ad) study protocol. this cohort of patients will receive a maximum of 3 \[11c\]acetoacetate (acac)/\[18f\]fluorodeoxyglucose (fdg) pet scans over 18 weeks as part of this supplemental trial.

the main objective of this study is to examine the brain biodistribution of \[11c\]acac/\[18f\]fdg, a proxy for acetoacetate (ketone body)/glucose metabolism in 3 study groups; 1) those without identifiable risk of alzheimer's disease, 2) asymptomatic individuals with increased risk of alzheimer's disease (such as pre diabetes),and 3) those with early alzheimer's disease or mci. secondary objectives include determining the association between adipose tissue distribution/function and biomarkers of ad pathology.

Eligibility criteria:
inclusion criteria: * mild cognitive impairment or subjective memory complaints * stable medical condition and medications * ability to complete baseline assessments exclusion criteria: * history of a clinically significant stroke * sensory impairment (visual, auditory) * diabetes requiring medication * current use of cholesterol/lipid lowering medications, anticonvulsants, drugs with potential interfering cns effects (other than cholinesterase inhibitors or memantine), medications with significant anticholinergic activity, anti-parkinsonian medications or regular use of narcotic analgesics * untreated hypothyroidism or b12 deficiency

Keywords: memory cognitive
emergency surgery following pediatric catheterization

Conditions: Anesthesia

Summary: we study the outcome and prequesties of emergency surgeries that were necessary following accidents in the pediatric cardiac catheterization lab


Eligibility criteria:
inclusion criteria: * patients presenting for diagnostic or therapeutic pediatric cardiac catheterization exclusion criteria: * none
assessment of thyroid dysfunction in patients undergoing haemodialysis at sohag university hospital

Conditions: Dialysis; Complications

Summary: thyroid dysfunction is a prevalent endocrine disorder that significantly impacts the health of patients with chronic kidney disease (ckd), particularly those undergoing dialysis. the prevalence of thyroid dysfunction in dialysis patients has been reported to range from 20% to 60%, highlighting the need for routine screening and management in this vulnerable group (kuo et al., 2024). thyroid hormones play a crucial role in regulating various physiological processes, and their dysregulation can lead to complications such as cardiovascular disease, anemia, and impaired quality of life, which are particularly concerning in the dialysis population (smith et al., 2024). the relationship between ckd and thyroid dysfunction is complex and multifactorial. uremic toxins can interfere with the hypothalamic-pituitary-thyroid axis, leading to alterations in thyroid hormone production and metabolism. recent studies have shown that inflammation and oxidative stress associated with ckd can further exacerbate thyroid dysfunction (johnson et al., 2024). understanding these mechanisms is essential for developing effective management strategies for thyroid health in dialysis patients.


Eligibility criteria:
inclusion criteria: * adults aged 18 years and older. * patients diagnosed with end-stage renal disease (esrd) on regular hemodialysis for at least 3 months. exclusion criteria: * known thyroid disorders: patients with a history of thyroid disease (e.g., hypothyroidism, hyperthyroidism) prior to starting dialysis. * recent thyroid treatment: patients who have received treatment for thyroid dysfunction (e.g., thyroid hormone replacement, antithyroid medications) within the last six months. * patients with acute kidney injury (aki) or those who are not on regular dialysis. * pregnant or lactating women. * patients with systemic illnesses or medications that could interfere with thyroid function tests (e.g., corticosteroids, lithium).
recording high frequency oscillations in patients with tumors and epilepsy

Conditions: Epilepsy; Tumor

Summary: the investigators want to characterize high-frequency oscillations (hfos) in intracranial recordings, which may occur as markers of epileptogenic tissue and also under physiological stimulation. the investigators want to show that recording of high-frequency oscillations (hfos) is feasible in our project population both intraoperatively and during presurgical physiological conditions.


Eligibility criteria:
inclusion criteria: * patients intend to be treated at the klinik für neurochirurgie * patients fall into one of the patient groups: (1) patients with symptomatic epilepsy with focal and/or secondary generalized seizures resistant to medication where a neurosurgical resection is considered as an intervention of epilepsy surgery. (2)patients where a tumor is planned to be resected that has caused preoperative seizures. (3) patients where a tumor is planned to be resected that has not caused preoperative seizures. * male and female subjects 18 years to 99 years of age * written informed consent after participants' information exclusion criteria: * contraindications on ethical grounds * known or suspected non-compliance, drug or alcohol abuse, * enrolment into a clinical trial within last 4 weeks
preoperative endoscopic pancreatic stent for distal pancreatectomy

Conditions: Pancreatectomy; Pancreatic Fistula

Summary: distal pancreatectomy (dp) with or without splenectomy is commonly indicated for pancreatic body or tail lesions. postoperative pancreatic fistula (popf) remains the commonest complication after dp. a pre-operatively placed pancreatic stent across papilla can decrease the pressure gradient between pancreatic duct and duodenum. therefore, the pancreatic juice flow is redirected from the pancreatic transection plane and leakage from pancreatic stump is much reduced. this study aims to evaluate whether pre-operatively placed pancreatic stent can prevent popf by a randomized controlled trial.

a randomised-controlled trial is performed to evaluate the efficacy of preoperative pancreatic duct stenting in preventing post-operative pancreatic fistula after distal pancreatectomy with or without splenectomy. patients will be randomised to pre-operative stent group or surgery alone group. pre-operative pancreatic duct stenting will be performed 1-2 weeks before surgery. the stent will be removed 4 weeks after operation. the post-operative pancreatic fistula rate, morbidity, mortality and total length of stay were compared between the 2 groups.

Eligibility criteria:
inclusion criteria: * age \>18 years * elective distal pancreatectomy for primary pancreatic pathology exclusion criteria: * informed consent not available * emergency distal pancreatectomy * presence of pancreatic duct stricture * presence of altered anatomy that precludes safe endoscopic retrograde cholangiography (e.g. previous billroth ii gastrectomy) * history of severe pancreatitis

Keywords: distal pancreatectomy pancreatic fistula
psma-based 18f-dcfpyl pet/ct: evaluating its application in real life

Conditions: Prostate Cancer

Summary: the purpose of the study is to provide pilot data on the clinical situations in which ordering a 18f-dcfpyl positron emission tomography/computed tomography (pet/ct) was thought to be clinically useful, and to document how the results of the 18f-dcfpyl pet/ct affected patient management. the results of this study could then serve as a guide to help ohip to consider these scenarios when deciding the precise indications for funded 18f-dcfpyl pet/ct scans in the future. in this study the investigators will image subjects with prostate cancer using 18f-dcfpyl pet/ct and record how the result of the study affected patient management.


Eligibility criteria:
inclusion criteria: * willing and able to provide written informed consent * age ≥ 18 years and male * histologically or cytologically confirmed adenocarcinoma of the prostate * eastern cooperative oncology group (ecog) performance status of ≤ 2 * one of the following: * ct scan showing indeterminate lymph node(s) in the pelvis that could potentially be treated radically with radiotherapy if found to be positive on psma pet. * suspected oligometastatic disease (\< 4 sites of disease) that could potentially be treated with stereotactic/radical doses of radiotherapy. exclusion criteria: * serious or uncontrolled co-existent non-malignant disease, including active and uncontrolled infection * uncontrolled hypertension (systolic bp ≥ 160 mmhg or diastolic bp ≥ 95 mmhg) * condition or situation which, in the investigator's opinion, may put the subject at significant risk, may confound the study results, or may interfere significantly with subject's participation in the study * not willing to comply with the procedural requirements of this protocol * subjects who have partners of childbearing potential who are not willing to use a method of birth control with adequate barrier protection as determined to be acceptable by the principal investigator and sponsor during the study and for 13 weeks after last study drug administration.
safety and feasibility study of intranasal mesenchymal trophic factor (mtf) for treatment of asthma

Conditions: Asthma

Summary: allogeneic mesenchymal trophic factors (mtf) from human umbilical cord tissue-derived mesenchymal stem cells (uc-msc) administered intra-nasally to 20 patients is a safe and useful procedure for inducing improvements in pulmonary function and quality of life in patients with asthma.

the proposed study will assess primary safety and secondary efficacy endpoints of allogeneic uc-msc-derived mtf administered to patients with asthma. each patient will receive intra-nasal mtf once per week for a period of 4 weeks.

Eligibility criteria:
inclusion criteria: * signed consent form by the subject * male or female * between 18 and 65 years old and capability to comprehend this trial. * asthma diagnosed by a physician at least 1 year prior to study enrollment * poorly-controlled asthma at study enrollment. poorly controlled asthma is defined as: chronic symptoms, episodic exacerbations, persistent and variable airways obstruction despite a continued requirement for short-acting beta 2-agonists despite the use of high doses of inhaled steroids. * nonsmokers (stopped smoking at least 1 year ago) and limited life-time history of smoking (less than a 3 pack year history). * body mass index 19-40 * on a stable dose of inhaled corticosteroid for at least 4 weeks prior to study entry or had to use a rescue dose during the last 4 weeks. * fev1 \>50% predicted exclusion criteria: * pregnant or lactating women * cognitively impaired adults * systemic steroids within the 4 weeks prior to enrollment * non-steroidal anti-inflammatory drugs (nsaids) for arthritis * current diagnosis of polyposis or sinusitis. * infection treated by antibiotics within the 4 weeks prior to enrollment * immunization within the 4 weeks prior to enrollment * lung pathology other than asthma * other significant non-pulmonary co-morbidities such as: coronary artery disease, peripheral vascular disease, cerebrovascular disease, congestive heart failure with an ejection fraction \ 3.0, or disorders requiring steroid treatment such as vasculitis, lupus, rheumatoid arthritis * illicit drug use within the past year * current/active upper respiratory infection (uri) (if active uri, wait until asymptomatic for 1 week to enroll) * asthma exacerbation within the 4 weeks prior to enrollment (includes er, urgent care, or hospital visits due to asthma resulting in an increase in asthma-related medications) * undergoing evaluation for sleep apnea, or plans to institute treatment for sleep apnea (patients on a stable treatment regimen for sleep apnea for the last 3 months prior to enrollment will be allowed to participate) * clinically significant abnormalities present on screening 12-lead electrocardiogram * women of childbearing potential using oral contraceptives who are not willing to use a second method of contraception during the study * participation in another clinical study within 4 weeks prior to enrollment * subject does not sign informed consent

Keywords: asthma umbilical cord mesenchymal stem cells trophic factors
radiotherapy, cetuximab, and injections of tnferade™ biologic for elderly or frail patients with head and neck cancer

Conditions: Head and Neck Cancer; Head and Neck Neoplasms

Summary: this study is looking at the safety and tolerability of tnferadeä biologic combined with conventional once daily radiation therapy in elderly or frail patients with new onset locally advanced head and neck tumors.


Eligibility criteria:
inclusion criteria: * age 70 or older with an ecog performance status 0-2,or * patients \> 18 years of age with ecog performance status of 2 or greater, or * patients \> 18 years of age unsuitable for concurrent chemotherapy or surgery due to: * renal failure, or * severe cardiopulmonary disease, or * other end-organ dysfunction that precludes the use of chemotherapy but does not preclude the administration of tnferade™ biologic or cetuximab * tumor that is unresectable or inoperable and not amenable to regular concurrent chemoradiotherapy * patients \> 18 years of age with intermediate stage disease, stages ii-iii (t2-t3, n0-1mo) carcinoma of the head and neck, including oral cavity, pharynx larynx, paranasal sinuses and cervical esophagus. selected patients with stage iv disease (t4n0-1m0) will also be considered for enrollment. therapy is given with curative intent. * disease should be clinically accessible (measurable or evaluable) to keep injection via direct intratumoral injection * informed consent exclusion criteria: * history of malignancy in the last 2 years except carcinoma in situ of the cervix or bladder, non-melanomatous skin cancer, or localized early stage prostate cancer, with patients continually disease free, or cancers that are not felt to influence treatment for head and neck cancer and life expectancy of patient * overt systemic metastatic disease * previous radiation or chemotherapy for malignancy of the head and neck * clinical evidence of active infection of any type * pregnant or lactating women * experimental medications within the last 4 weeks prior to day 1 * chronic treatment for greater than 6 months with steroids at doses above 10 mg/day prednisone (or equivalent) * patients receiving hormone replacement therapy or hormonal contraceptives within 2 weeks of day 1 * patients who have undergone surgery within the last 1 month * allergic reaction to cetuximab

Keywords: head neck cancer neoplasm
1-week dispensing evaluation of revive™ toric soft contact lenses

Conditions: Refractive Ametropia

Summary: experienced soft contact lens wearing subjects will be enrolled in this 1-week, post-market, bilateral, repeated measures, dispensing study. all subjects will be seen for a screening/dispensing visit at which informed consent will be obtained and eligibility will be assessed. if subjects satisfy all eligibility criteria and none of the exclusion criteria, subjects will be fit and dispensed study lenses. if unsuccessful in the dispensed lenses, additional lenses may be trialed. once vision and lens fit are determined to be acceptable, eligible subjects will wear study lenses in both eyes for at least 8 hours per day (with the exception of the follow-up visits where the lenses should be worn for a minimum of 2 hours), for approximately 1 week (7 days +/-3 days). measurements will be taken at the insertion visit and at the 7-day follow-up visit.


Eligibility criteria:
inclusion criteria: 1. be 18 years or older on the date the informed consent form (icf) is signed and have capacity to read, understand and provide written voluntary informed consent. 2. have physiologically normal anterior segments not exhibiting clinically significant biomicroscopy findings. 3. have no active ocular disease or allergic conjunctivitis. 4. not be using any topical ocular medications. 5. be willing and able to follow instructions. 6. have signed a statement of informed consent exclusion criteria: 1. participating in a conflicting study in the opinion of the investigator. 2. considered by the investigator to not be a suitable candidate for participation.